Woman of the Week: AiCure's Michelle Marlborough

As chief product officer at AiCure, Michelle Marlborough is focused on solving tough patient challenges through technology.

By Taren Grom • May 11, 2022

Where hope and uncertainty meet: A cutting-edge cancer developer's winding road

Replimune is on the precipice of a new kind of cancer treatment, but its CEO knows something about ambiguity.

By Alexandra Pecci • May 9, 2022

Explore the Trendline➔

Commercialization, marketing and social media

As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical. 

By PharmaVoice staff

Woman of the Week: Amgen's Dr. Jane Parnes

As executive medical director, early development at Amgen, Dr. Jane Parnes has helped guide clinical research for upwards of 30 of the company’s investigational molecules, including the newly approved Tezspire for severe asthma — one of her career highlights.

By Taren Grom • May 4, 2022

Bayer executive makes strides toward a finish line for rare cancers

Bayer's SVP and general manager of U.S. oncology completed the Boston Marathon to honor his brother and bring attention to rare cancers.

By Alexandra Pecci • May 3, 2022

One company's failed drug is this company's 'jewel'

Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.

By Meagan Parrish • May 2, 2022

Woman of the Week: Gilead Science's Dr. Shanthi Ganeshan

As vice president of Global Regulatory Affairs, Oncology at Gilead, Ganeshan says there’s ‘never a dull moment’ in the quest to deliver therapies to patients.

By Taren Grom • April 27, 2022

Mouse vs. machine: Using AI to solve the animal testing model in pharma

Quris is bringing its first drug tested preclinically using AI — rather than animal models — into human trials.

By Michael Gibney • April 26, 2022

Woman of the Week: Aura Biosciences' Dr. Elisabet de los Pinos

Dr. Elizabet de los Pinos, CEO and founder of Aura Biosciences, had a dream at a young age to change the course of cancer treatment and understand the underlying DNA of the disease.

By Taren Grom • April 20, 2022

With Lilly on board, Entos' medical chief champions genetic platform with 'unlimited' potential

 Steve Chen is helping to lead Entos through an ‘inflection point’ in the development of its precision medicine delivery platform.

By Alexandra Pecci • April 14, 2022

Biotech goes Hollywood

A few years ago, the biotech venture world in LA was almost ‘nonexistent’ — now Joseph Panetta, CEO of Biocom California, says the region is undergoing a major change.

By Taren Grom • April 13, 2022

Why the war in Ukraine could accelerate the deglobalization of clinical trials

COVID-19 slowed many studies — but the war could further strain clinical trials worldwide.

By Michael Gibney • April 12, 2022

Woman of the Week: Lyell Immunopharma's Liz Homans

The CEO has the company poised to capitalize on its moment to address T cell exhaustion.

By Taren Grom • April 6, 2022

A planned trial revives a glimmer of hope for a Huntington's disease treatment

Roche brought a Huntington’s drug back to life after a jarring trial halt.

By Kelly Bilodeau • April 6, 2022

Seeing yourself at the top: Alnylam CEO on why representation matters

Dr. Yvonne Greenstreet became just the sixth woman in the world to head up a biopharma company with a market cap of more than $5 billion when she took on the role of CEO in January.

By Alexandra Pecci • April 6, 2022

An analyst turned pharma CEO learns the art of operations

Under Apurva Saraf’s guidance, Cosette Pharmaceuticals is pivoting wholeheartedly into the cardio space.

By Jared Whitlock • April 5, 2022

Lessons from improv: Shankar Narayanan’s ‘yes, and’ approach to healthcare leadership

Real Chemistry's CEO is bringing a unique set of skills to the role as he sets off on a company-wide listening tour.

By Taren Grom • April 4, 2022

Sangamo has its finger on the next evolution of gene editing

Sangamo Therapeutics' CEO Sandy Macrae is bullish on his company’s ability to transform the genomic medicine arena.

By Taren Grom • March 31, 2022

Woman of the Week: Daré Bioscience's Sabrina Martucci Johnson

The CEO is setting a path to transform women’s health at an opportune time.

By Taren Grom • March 30, 2022

Woman of the Week: Merck's Dr. Mary-Ann Etiebet

The associate VP of health equity is on a quest to address the relationship between health, gender and economic opportunities.

By Taren Grom • March 23, 2022

BioMarin’s new global head of advocacy is tackling the holy grail of patient engagement

In her new role, Dr. Roz is keeping her patient-first approach.

By Taren Grom • March 21, 2022

Virpax's CEO on leveraging new formulations to move drugs toward approval

Anthony Mack shares his lessons from getting unconventional pharma products across the finish line.

By Meagan Parrish • March 18, 2022

How Novartis kept its supply chain intact during COVID-19

In an agile pivot, Amit Nastik led Novartis’ manufacturing operations through the pandemic without losing supply chain reliability. 

By Taren Grom • March 16, 2022

Woman of the Week: Ceek Women's Health CEO Fahti Khosrowshahi

Fahti Khosrowshahi, CEO and founder, Ceek Women’s Health, is designing award-winning products to change the face of women's health. 

By Taren Grom • March 16, 2022

Biote CEO: Employers need to normalize women's health issues in the workforce

A survey by Biote reveals the impact of menopause on working women.

By Robin Robinson • March 14, 2022

From angel to operator: The unlikely journey of Endevica Bio's CEO

Russell Potterfield is honing his new found passion for the space to guide Endevica into the clinic.

By Jared Whitlock • March 9, 2022